Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Iron deficiency may impair aerobic performance. This study aimed to determine whether treatment with intravenous iron (ferric carboxymaltose) would improve symptoms in patients who had heart failure, reduced left ventricular ejection fraction, and iron deficiency, either with or without anemia. METHODS: We enrolled 459 patients with chronic heart failure of New York Heart Association (NYHA) functional class II or III, a left ventricular ejection fraction of 40% or less (for patients with NYHA class II) or 45% or less (for NYHA class III), iron deficiency (ferritin level <100 microg per liter or between 100 and 299 microg per liter, if the transferrin saturation was <20%), and a hemoglobin level of 95 to 135 g per liter. Patients were randomly assigned, in a 2:1 ratio, to receive 200 mg of intravenous iron (ferric carboxymaltose) or saline (placebo). The primary end points were the self-reported Patient Global Assessment and NYHA functional class, both at week 24. Secondary end points included the distance walked in 6 minutes and the health-related quality of life. RESULTS: Among the patients receiving ferric carboxymaltose, 50% reported being much or moderately improved, as compared with 28% of patients receiving placebo, according to the Patient Global Assessment (odds ratio for improvement, 2.51; 95% confidence interval [CI], 1.75 to 3.61). Among the patients assigned to ferric carboxymaltose, 47% had an NYHA functional class I or II at week 24, as compared with 30% of patients assigned to placebo (odds ratio for improvement by one class, 2.40; 95% CI, 1.55 to 3.71). Results were similar in patients with anemia and those without anemia. Significant improvements were seen with ferric carboxymaltose in the distance on the 6-minute walk test and quality-of-life assessments. The rates of death, adverse events, and serious adverse events were similar in the two study groups. CONCLUSIONS: Treatment with intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency, with or without anemia, improves symptoms, functional capacity, and quality of life; the side-effect profile is acceptable. (ClinicalTrials.gov number, NCT00520780).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Likewise, parenteral iron substitution has been found to improve the clinical course of CHF in patients with coexisting ID [22–24].”
From Iron deficiency or anemia of inflammation?: Differential diagnosis and mechanisms of anemia of inflammation (2016) · cites this paper as [24]
In the citing paper
“We are aware that anemia is a complication of iron deficiency, though not the only one, since other tissues/organs may be iron-depleted before anemia develops, as occurs in chronic heart failure.75”
From Iron metabolism and iron disorders revisited in the hepcidin era (2020) · cites this paper as [75]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
EQ-SD: a measure of health status from the EuroQol Group
Rabin, R., & Charro, F. D. (2001) · Annals of Medicine · doi:10.3109/07853890109002087 · Cited by 5,613
Regression Models for Ordinal Data
McCullagh, P. (1980) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1980.tb01109.x · Cited by 4,453
2005 WRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192065 · Cited by 3,720
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
Dickstein, K., Authors/Task Force Members, Cohen-Solal, A., Filippatos, G., McMurray, J. J. V., Ponikowski, P., Poole-Wilson, P. A., Strömberg, A., van Veldhuisen, D. J., Atar, D., et al. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.08.005 · Cited by 3,512
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Trends in Heart Failure Incidence and Survival in a Community-Based Population
Roger, V. L. (2004) · JAMA · doi:10.1001/jama.292.3.344 · Cited by 1,600
Jessup, M., & Brozena, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021498 · Cited by 1,564
Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., Michl, K., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.11.013 · Cited by 1,374
Haas, J. D., & Brownlie, T. (2001) · The Journal of Nutrition · doi:10.1093/jn/131.2.676s · Cited by 1,186
Research works printed but not linked: 4
- Fairbanks V, Beutler E. Iron deficiency. In: Beutler E, ed. Williams hematology. 6th ed. New York: McGraw-Hill, 2001:295-304, 447-70.
- Davies KJ, 1982, Am J Physiol, 242, E418
- Usmanov RI, 2008, J Nephrol, 21, 236
- Ganzoni AM, 1970, Schweiz Med Wochenschr, 100, 301
Cited by
Items 801–900 of 1,002
Sindone, A. P., Doehner, W., Manito, N., McDonagh, T. A., Solal, A. C., Damy, T., Núñez, J. E., Pfister, O., van der Meer, P., & Colet, J. C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11112976 · Cited by 23
“The largest randomised controlled trials to evaluate FCM in patients who were irondeficient nd had stable CHF (LVEF ≤ 45%) were the FAIR-HF [15], CONFIRM-HF [17], EFFECT-HF [18] and AFFIRM-AHF [16] studies.”
BackgroundMethodInfluentialDzięgała, M., Kobak, K. A., Kasztura, M., Bania, J., Josiak, K., Banasiak, W., Ponikowski, P. P., & Jankowska, E. A. (2018) · Cells · doi:10.3390/cells7100175 · Cited by 19
Self-citationAnabolism to Catabolism: Serologic Clues to Nutritional Status in Heart Failure
Murphy, L., Gray, A. P., & Joyce, E. (2019) · Current Heart Failure Reports · doi:10.1007/s11897-019-00437-y · Cited by 21
Time to Reconsider Evidence for Anaemia Treatment (TREAT) = Essential Safety Arguments (ESA)
Goldsmith, D. J. A., & Covic, A. C. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq099 · Cited by 18
Szabó, T., Doehner, W., & Anker, S. D. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1002215 · Cited by 21
Self-citationGarcía‐Escobar, A., Lázaro-García, R., Goicolea-Ruigómez, J., Pizarro, G., y, A. J.-R., Moreno, R., & Cabrera, J. Á. (2024) · Cardiac failure review · doi:10.15420/cfr.2024.17 · Cited by 20
Anemia Management in the Cardiorenal Patient: A Nephrological Perspective
Marqués, M., Portolés, J. M., Marcos, M. C., Gorriz, J. L., Núñez, J. E., & Cases, A. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.037363 · Cited by 23
“57 These results were confirmed in a recent meta-analysis with ferric carboxymaltose that included the HEART-FID trial 63 and another meta-analysis, which may explain the lack of benefit of intravenous iron seen in HEART-FID trial.”
Duca, L., Pierro, E. D., Scaramellini, N., Granata, F., & Graziadei, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136433 · Cited by 24
“Clinical studies have identified iron, with and without anemia, in patients with chronic heart failure and reduced ejection fraction [40].”
Patient-Reported Outcomes in Patients with Cardiomyopathy
Garcia, R. A., Benton, M. C., & Spertus, J. A. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01511-5 · Cited by 18
Massaiu, I., Campodonico, J., Mapelli, M., Salvioni, E., Valerio, V., Moschetta, D., Myasoedova, V. A., Cappellini, M. D., Pompilio, G., Poggio, P., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032887 · Cited by 21
“In particular, it has been shown that intravenous iron supplementation improves the quality of life and exercise capacity, and reduces re-hospitalization in patients with HF and ID [23,25].”
BackgroundGan, S., Azzo, J. D., Zhao, L., Pourmussa, B., Dib, M., Salman, O., Erten, O., Ebert, C., Richards, M., Javaheri, A., et al. (2025) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.011728 · Cited by 22
Hemoglobin Kinetics and Long-term Prognosis in Heart Failure
Díez‐López, C., Lupón, J., de Antonio, M., Zamora, E., Domingo, M., Santesmases, J., Troya, M. I., Boldo, M., & Bayés‐Genís, A. (2016) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2016.02.028 · Cited by 18
Kim‐Mitsuyama, S., Soejima, H., Yasuda, O., Node, K., Jinnouchi, H., Yamamoto, E., Sekigami, T., Ogawa, H., & Matsui, K. (2019) · Hypertension Research · doi:10.1038/s41440-019-0210-1 · Cited by 23
Iron Deficiency as a Therapeutic Target in Cardiovascular Disease
Lakhal‐Littleton, S. (2019) · Pharmaceuticals · doi:10.3390/ph12030125 · Cited by 19
A Meta-analysis of Intravenous Iron Therapy for Patients With Iron Deficiency and Heart Failure
Osman, M., Syed, M., Balla, S., Kheiri, B., Faisaluddin, M., & Bianco, C. M. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.11.025 · Cited by 17
Iron Deficiency Without Anemia – Common, Important, Neglected
Soppi, E. T. (2019) · Clinical Case Reports and Reviews · doi:10.15761/ccrr.1000456 · Cited by 28
Zhang, Z., Chang, C. C., Zhang, Y., Chai, Z., Li, J., & Qiu, C. (2021) · Scientific Reports · doi:10.1038/s41598-021-93873-7 · Cited by 17
del Canto, I., Santas, E., Cardells, I., Miñana, G., Palau, P., Llàcer, P., Fácila, L., López‐Vilella, R., Almenar, L., Bodí, V., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.022214 · Cited by 16
von Drygalski, A., & Adamson, J. W. (2011) · Blood · doi:10.1182/blood-2011-07-366120 · Cited by 17
Miñana, G., Cardells, I., Palau, P., Llàcer, P., Fácila, L., Almenar, L., López-Lereu, M. P., Monmeneu, J. V., Amiguet, M., González, J., et al. (2018) · Clinical Cardiology · doi:10.1002/clc.22956 · Cited by 18
Incident anaemia in older adults with heart failure: rate, aetiology, and association with outcomes
Ambrosy, A. P., Gurwitz, J. H., Tabada, G. H., Artz, A. S., Schrier, S. L., Rao, S. V., Barnhart, H. X., Reynolds, K., Smith, D. H., Peterson, P. N., et al. (2019) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcz010 · Cited by 20
Martens, P., Dupont, M., Dauw, J., Somers, F., Herbots, L., Timmermans, P., Verwerft, J., & Müllens, W. (2019) · ESC Heart Failure · doi:10.1002/ehf2.12503 · Cited by 18
Jelani, Q., & Katz, S. D. (2010) · Cardiology in Review · doi:10.1097/crd.0b013e3181e71150 · Cited by 20
ANAEMIA MANAGEMENT IN CARDIO RENAL DISEASE
Silverberg, D. S., Wexler, D., Iaina, A., & Schwartz, D. (2010) · Journal of Renal Care · doi:10.1111/j.1755-6686.2010.00164.x · Cited by 18
de Isla, L. P., Bayés‐Genís, A., Sanchís, J. M., & Heras, M. (2010) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(10)70037-2 · Cited by 16
Iron deficiency and short-term adverse events in patients with decompensated heart failure
Palau, P., Llàcer, P., Domínguez, E., Tormo-Juárez, J. P., Zakarne, R., Mollar, A., Martínez, A., Miñana, G., Santas, E., Bonet, L. A., et al. (2021) · Clinical Research in Cardiology · doi:10.1007/s00392-021-01832-z · Cited by 19
Vlahakos, V., Marathias, K. P., Lionaki, S., Loukides, S., Zakynthinos, S. G., & Vlahakos, D. (2022) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2022.2045958 · Cited by 19
“Heart Association Class, the 6-minute walk test, the quality of life and the risk for hospitalization, but failed to reduce mortality [67,68].”
BackgroundIron homeostasis in the heart: Molecular mechanisms and pharmacological implications
Zhang, J., Song, Y., Li, Y., Lin, H.-B., & Fang, X. (2022) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2022.11.001 · Cited by 17
A Role of Sodium-Glucose Co-Transporter 2 in Cardiorenal Anemia Iron Deficiency Syndrome
Sano, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065983 · Cited by 18
“The Ferinject Assessment in Patients with Iron Deficiency and Chronic Heart Failure (FAIR-HF) trial, which evaluated Ferinject® (ferric carboxymaltose) in patients with iron deficiency and chronic heart failure, showed that intravenous administration of the iron agent ferric carboxymaltose improves symptoms, exercise…”
BackgroundGeorgopoulou, T., Petrakis, I., Dermitzaki, K. E., Pleros, C., Drosataki, E., Aletras, G., Foukarakis, E. G., Lioudaki, E., Androulakis, E. S., & Stylianou, K. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12124121 · Cited by 25
The treatment of chronic anemia in heart failure: a global approach
Bianchi, V. E., & von Haehling, S. (2023) · Clinical Research in Cardiology · doi:10.1007/s00392-023-02275-4 · Cited by 22
“The search identified sixteen studies [36–51] summarized in Table 1: eight studies evaluated the effect of intravenous (i.v.) ferric carboxymaltose [38–41, 43, 52–54], six the effect of darbepoetin alfa [23, 44–47, 49, 55] and two the effects of erythropoietin [45, 56].”
Defining iron replete status in patients with heart failure treated with intravenous iron
Talha, K. M., Butler, J., von Haehling, S., Lainščak, M., Ponikowski, P. P., & Anker, S. D. (2023) · Global Cardiology · doi:10.4081/cardio.2023.17 · Cited by 19
Self-citationMadonna, R., Biondi, F., Alberti, M., Ghelardoni, S., Mattii, L., & D’Alleva, A. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116650 · Cited by 19
Yang, M., Kondo, T., Talebi, A., Jhund, P. S., Docherty, K. F., Claggett, B. L., Vaduganathan, M., Bachus, E., Hernandez, A. F., Lam, C. S. P., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3263 · Cited by 20
Self-citationUsing multiple primary endpoints in clinical trials with a focus on heart failure
Anker, S. D., Butler, J., Talha, K. M., & Friede, T. (2024) · Global Cardiology · doi:10.4081/cardio.2024.33 · Cited by 23
Self-citationSato, R., Koziolek, M. J., & von Haehling, S. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.10.024 · Cited by 19
Sobrado, C. W., Cançado, R. D., Sobrado, L. F., Frugis, M. O., & Sobrado, M. F. (2015) · Arquivos de Gastroenterologia · doi:10.1590/s0004-28032015000400002 · Cited by 16
Iron deficiency in heart failure: Efficacy and safety of intravenous iron therapy
Kang, C. K., Pope, M., Lang, C. C., & Kalra, P. R. (2017) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12301 · Cited by 18
Wang, J., Radics, G., Whelehan, M., OʼDriscoll, A., Healy, A. M., Gilmer, J. F., & Ledwidge, M. T. (2017) · Acta Haematologica · doi:10.1159/000480632 · Cited by 16
Why is Iron Deficiency Recognised as an Important Comorbidity in Heart Failure?
Ebner, N., & von Haehling, S. (2019) · Cardiac failure review · doi:10.15420/cfr.2019.9.2 · Cited by 20
“In recent years, different therapeutic possibilities embrace iron replacement by oral or IV routes.(9,12,17) The IV route is more effective than the oral route, mostly as a consequence of the limited absorption capacity in the duodenum and due to the side-effects of oral iron therapy that are encountered in up to 20%…”
BackgroundZügel, M., Treff, G., Steinacker, J. M., Mayer, B., Winkert, K., & Schümann, U. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2019.01577 · Cited by 19
“Furthermore, consensus exists that the diagnosis of functional ID should include serum ferritin levels as well as transferrin saturation (Anker et al., 2009; Eisenga et al., 2016).”
BackgroundMethodRight ventricular function and iron deficiency in acute heart failure
Miñana, G., Santas, E., de la Espriella, R., Núñez, E., Lorenzo, M., Núñez, G., Valero, E., Bodí, V., Chorro, F. J., Sanchís, J. M., et al. (2020) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuaa028 · Cited by 19
Tkaczyszyn, M., Colet, J. C., Voors, A. A., van Veldhuisen, D. J., Enjuanes, C., Moliner, P., Drozd, M., Sierpiński, R., Rozentryt, P., Nowak, J. U., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2253 · Cited by 18
Self-citationPérez-Peiró, M., Martín‐Ontiyuelo, C., Rodó‐Pin, A., Piccari, L., Admetlló, M., Durán, X., Rodriguez, D. A., & Barreiro, E. (2021) · Biomedicines · doi:10.3390/biomedicines9091191 · Cited by 23
Biomarkers in the clinical management of patients with atrial fibrillation and heart failure.
Koniari, I. C., Artopoulou, E., Velissaris, D., Ainslie, M., Mplani, V., Karavasili, G., Kounis, N. G., & Tsigkas, G. (2021) · PubMed Central · doi:10.11909/j.issn.1671-5411.2021.11.010 · Cited by 25
“According to some studies, iron deficiency is connected with exercise capacity and patients with chronic heart failure show clinical and functional improvementwith iron replacement therapy, however,the cause of anemia in those cases wasmost likely associated with chronic renal failure, decreasedplasma erythropoietin,…”
BackgroundContemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction
Vishram‐Nielsen, J. K. K., Tomasoni, D., Gustafsson, F., & Metra, M. (2022) · Drugs · doi:10.1007/s40265-021-01666-z · Cited by 19
Suryani, L. D., Raharjo, S. B., Sagita, R., Prasetyadi, Y. L., Suyatna, F. D., Hersunarti, N., Soerarso, R., Siswanto, B. B., & Muliawan, H. S. (2022) · Global Heart · doi:10.5334/gh.1151 · Cited by 17
“This drug improved haemoglobin, ferritin, transferrin saturation and functional capacity [8, 9].”
InfluentialAnemia and Iron Deficiency in Heart Failure
Gunawardena, S., & Dunlap, M. E. (2012) · Current Heart Failure Reports · doi:10.1007/s11897-012-0112-x · Cited by 22
Cooper, T. J., Anker, S. D., Colet, J. C., Filippatos, G. S., Lainščak, M., Lüscher, T. F., Mori, C., Johnson, P. C., Ponikowski, P. P., & Dickstein, K. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.02.018 · Cited by 16
Self-citationNext-Generation Biomarkers for Iron Status
Drakesmith, H. (2016) · Nestlé Nutrition Institute Workshop series · doi:10.1159/000436955 · Cited by 18
Iron Laboratory Studies in Pediatric Patients With Heart Failure from Dilated Cardiomyopathy
Higgins, D., Otero, J., Kirk, C. J., Pak, J. L., Jorgensen, N. W., Kemna, M. S., Albers, E. L., Hong, B. J., Friedland‐Little, J. M., & Law, Y. M. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.08.023 · Cited by 18
Dalal, J. J., Katekhaye, V., & Jain, R. (2017) · Indian Heart Journal · doi:10.1016/j.ihj.2017.10.009 · Cited by 18
“Two of them met the inclusion criteria.(25,26) while one was excluded on the grounds of retrospective study design.”
BackgroundAbraham, J., Sinha, R. K., Robinson, K. L., Scotland, V. J., & Cardone, D. (2017) · Anaesthesia and Intensive Care · doi:10.1177/0310057x1704500107 · Cited by 16
Anguita, M. P., Colet, J. C., Almenar, L., Crespo, M., Delgado, J. F., González‐Costello, J., Hernández‐Madrid, A., Manito, N., de la Sota, E. P., Segovia, J., et al. (2012) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2012.07.005 · Cited by 16
Chronic Kidney Disease and End Stage Renal Disease
Martinusen, D. J., Marin, J., Cheng, E., & Lau, W. (2020) · Advanced clinical pharmacy - research, development and practical applications/Advanced clinical pharmacy - research, development and practical applications · doi:10.1007/978-3-030-37655-0_4 · Cited by 24
Garcia, R. A., & Spertus, J. A. (2021) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/vuwd7697 · Cited by 18
Arsiwala, T., Vogt, A. S., Barton, A. E., Manolova, V., Funk, F., Flühmann, B., & Bachmann, M. F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052666 · Cited by 16
Short-term treatment of iron deficiency anemia after cardiac surgery
Venturini, E., Iannuzzo, G., Lorenzo, A. D., Cuomo, G., D’Angelo, A., Merone, P., Cudemo, G., Pacileo, M., D’Andrea, A., Vigorito, C., et al. (2022) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2022.101038 · Cited by 21
Iron deficiency and pulmonary arterial hypertension
Lan, M., Wu, S., & Fernandes, T. M. (2022) · Nutrition in Clinical Practice · doi:10.1002/ncp.10884 · Cited by 16
Iron deficiency in heart failure: diagnosis and clinical implications
Pinto, R. D., & Ferri, C. (2022) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suac080 · Cited by 16
“In the FAIR-HF study (Ferric Carboxymaltose Assessment in Patients With Iron Deficiency and Chronic Heart Failure), conducted on 459 outpatients with chronic heart failure (New York Heart Association, NYHA, II or III) treated, in a 2:1 ratio, with intravenous ferric carboxymaltose on a weekly basis until normal blood…”
ResultIron deficiency, anemia, and patient-reported outcomes in kidney transplant recipients
Kremer, D., Knobbe, T. J., Vinke, J. S. J., Groothof, D., Post, A., Annema, C., Abrahams, A. C., van Jaarsveld, B. C., de Borst, M. H., Berger, S. P., et al. (2024) · American Journal of Transplantation · doi:10.1016/j.ajt.2024.03.017 · Cited by 20
Functional iron deficiency anemia in patients with cancer
Koh, J. S., & Song, I. (2024) · Blood Research · doi:10.1007/s44313-024-00030-w · Cited by 22
“In patients with chronic kidney disease, it is delineated as ferritin levels not exceeding 500 µg and a TSAT of ≤ 30% [23, 24].”
BackgroundDoehner, W., Fischer, A., Alimi, B., Muhar, J., Springer, J., Altmann, C., & Schueller, P. O. (2024) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13628 · Cited by 19
Heart Failure and All-Cause Hospitalizations in Patients With Heart Failure: A Meta-Analysis
Sayed, A. A., ElRefaei, M., Awad, K., Salah, H., Mandrola, J. M., & Foy, A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.46684 · Cited by 17
Iron Deficiency in Heart Failure
Anand, I. S. (2014) · Cardiology · doi:10.1159/000361040 · Cited by 15
Pharmacological Management of Cardiorenal Syndromes
House, A. A., Haapio, M., Lassus, J. P. E., Bellomo, R., & Ronco, C. (2011) · International Journal of Nephrology · doi:10.4061/2011/630809 · Cited by 14
Cardiorenal Syndrome in End-Stage Kidney Disease
Tsuruya, K., Eriguchi, M., Yamada, S., Hirakata, H., & Kitazono, T. (2015) · Blood Purification · doi:10.1159/000441583 · Cited by 19
Lee, N. H. (2020) · Imsang soa hyeoraek jong-yang/Imsang soa hyeol'aeg jong'yang/Clinical pediatric hematology-oncology · doi:10.15264/cpho.2020.27.2.101 · Cited by 32
Anaemia and iron deficiency in chronic heart failure patients
Ватутин, Н. Т., Тарадин, Г. Г., Kanisheva, I. V., & Venzheha, V. V. (2019) · Kardiologiia · doi:10.18087/cardio.2638 · Cited by 23
“[104], посвященного изучению данных четырех двойных слепых РКИ у больных с СНнФВ и ЖД (FER-CARS-01, FAIR-HF [100], EFFICACY-HF и CONFIRM-HF [101]), отмечается их главный позитивный результат: лечение ВВПЖ ассоциируется с низкими уровнями повторных госпитализаций и смертности от сердечно-сосудистых осложнений.”
InfluentialMonitoring of iron status in patients with heart failure
Jankowska, E. A., Tkaczyszyn, M., Drozd, M., & Ponikowski, P. P. (2019) · European Heart Journal Supplements · doi:10.1093/eurheartj/suz231 · Cited by 18
“Therefore, currently accepted and recommended criteria for detecting ID in patients with HF are serum ferritin <100lg/L or serum ferritin 100–299lg/L in combination with Tsat <20%.(7,12,44) The aforementioned definition of ID has already been used in few major clinical trials in patients with symptomatic HF, where ID…”
BackgroundSelf-citationPrevalence and temporal trends of anemia in patients with heart failure
Rahman, E. U., Chobufo, M. D., Farah, F., Mohamed, T., El-Hamdani, M. O., Rueda, C., Aronow, W. S., Fonarow, G. C., & Thompson, E. R. (2021) · QJM · doi:10.1093/qjmed/hcab193 · Cited by 19
Intravenous Iron Replacement Improves Exercise Tolerance in COPD: A Single-Blind Randomized Trial
Martín‐Ontiyuelo, C., Rodó‐Pin, A., Echeverría-Esnal, D., Admetlló, M., Durán, X., Alvarado, M., Gea, J., Barreiro, E., & Rodriguez, D. A. (2021) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2021.08.011 · Cited by 18
Pintér, A., Behon, A., Veres, B., Merkel, E. D., Schwertner, W. R., Kuthi, L. K., Masszi, R., Lakatos, B. K., Kovács, A. D., Becker, D. J., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12020517 · Cited by 16
Anemia e deficiência de ferro na insuficiência cardíaca
Gil, V. M., & Ferreira, J. (2013) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2013.06.003 · Cited by 17
Herzinsuffizienz und Komorbiditäten
Widmer, F. (2011) · Therapeutische Umschau · doi:10.1024/0040-5930/a000127 · Cited by 17
Price, E. A., Artz, A. S., Barnhart, H. X., Sapp, S. K., Chelune, G. J., Ershler, W. B., Walston, J. D., Gordeuk, V. R., Berger, N. A., Reuben, D. B., et al. (2014) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2014.06.003 · Cited by 17
Drug therapies to delay the progression of chronic kidney disease
Ward, F. L., Holian, J., & Murray, P. T. (2015) · Clinical Medicine · doi:10.7861/clinmedicine.15-6-550 · Cited by 17
The Room Where It Happens: A Skeptic's Analysis of the New Heart Failure Guidelines
Packer, M. (2016) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2016.07.433 · Cited by 15
Detection of iron restriction in anaemic and non‐anaemic patients: New diagnostic approaches
Thomas, L., & Thomas, C. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12914 · Cited by 19
Zhang, S., Zhang, F., Du, M., Huang, K., & Wang, C. (2019) · British Journal Of Nutrition · doi:10.1017/s000711451900014x · Cited by 18
“Unlike intravenous supplementation, oral Fe supplementation increased transferrin concentration and serum Fe levels but did not improve peak oxygen uptake, 6-min walking distance, N-terminal pro-hormone of brain natriuretic peptide, Kansas City Anker, 2009((17)) Arutyunov, 2009((18)) Beck-da-Silva, 2013((19)) Okonko,…”
BackgroundMethodInfluentialNikolaou, M., Chrysohoou, C. A., Georgilas, T. A., Giamouzis, G., Giannakoulas, G. A., Karavidas, A. I., Papadopoulos, C. E., Patsilinakos, S. P., Tziakas, D. N., & Parissis, J. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.05.011 · Cited by 16
Cases, A., Puchades, M. J., de Sequera, P., Quiroga, B., Martín-Rodriguez, L., Górriz, J. L., & Portolés, J. M. (2021) · Nefrología · doi:10.1016/j.nefro.2020.11.003 · Cited by 24
Volterrani, M., Hálasz, G., Adamopoulos, S. N., Agostoni, P., Butler, J., Coats, A. J. S., Solal, A. C., Doehner, W., Filippatos, G., Jankowska, E. A., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3440 · Cited by 24
Self-citationPotential hazards of recent trends in liberal iron use for renal anemia
Nakanishi, T., & Kuragano, T. (2020) · Clinical Kidney Journal · doi:10.1093/ckj/sfaa117 · Cited by 14
“As a matter of course, in considering the beneficial effect of IV iron in the setting of congestive heart failure, further investigation should be essential for ascertaining whether our optimal ferritin range is appropriate in CKD patients [112, 113].”
BackgroundRosano, G. M. C., Kalantar‐Zadeh, K., & Jankowska, E. A. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14286 · Cited by 16
Kasprzak, J. D., Gorczyca-Głowacka, I., Sobczak, M., Barylski, M., Dróżdż, J., Filipiak, K. J., Kapłon‐Cieślicka, A., Lelonek, M., Mamcarz, A., Ochijewicz, D., et al. (2023) · Kardiologia Polska · doi:10.33963/kp.a2023.0110 · Cited by 26
No longer to be ignored: Hypophosphatemia following intravenous iron administration
Strubbe, M., David, K., Peene, B., Eeckhout, B., der Schueren, B. V., Decallonne, B., Vangoitsenhoven, R., Vanderschueren, D., & Antonio, L. (2024) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-024-09926-5 · Cited by 15
Cardioprotection by Hepc1 in cTnTR141W transgenic mice
Zhang, L., Lü, D., Zhang, W., Quan, X., Dong, W., Xu, Y., & Zhang, L. (2011) · Transgenic Research · doi:10.1007/s11248-011-9582-y · Cited by 16
Erythropoietin and Heart Failure: The End of a Promise?
Kleijn, L., Westenbrink, B. D., & van der Meer, P. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft058 · Cited by 14
Crișan, S., Petrescu, L., Lazar, M., Văcărescu, C., Nicola, A.-R., Cozma, D. C., Mornoş, C., & Luca, C. T. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s161385 · Cited by 17
“Also, control of iron deficiency, even in the absence of overt anemia, and consecutive treatment with ferric carboxymaltose, can lead to important symptomatic improvement in patients with chronic heart failure.(19,20) In elderly people, iron deficiency is even more strongly related to reduced quality of life because o…”
Relative hypochromia and mortality in acute heart failure
Kleber, M., Kozhuharov, N., Sabti, Z., Glatz, B., Isenreich, R., Wussler, D. N., Nowak, A., Twerenbold, R., Badertscher, P., Puelacher, C., et al. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.02.060 · Cited by 15
New drugs: big changes in conservative heart failure therapy?
Berliner, D., & Bauersachs, J. K. (2018) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezy421 · Cited by 14
“The effect was independent from concomitant anaemia [50].”
BackgroundMethodZdravkovic, S., Petrović-Nagorni, S., Ćojbašić, I., Mitic, V., Cvetković, P., Nagorni, I., Govedarović, N., Davinić, I., & Stanojević, D. (2019) · Journal of International Medical Research · doi:10.1177/0300060519847352 · Cited by 18
“However, as shown in other studies, treatment of irondependent anemia in HF significantly improved exercise tolerance (6MWD and NYHA class).(26) However, LVEF did not significantly increase in our patients as reported by other authors.”
ResultThe Effect of Iron Deficiency on Cardiac Resynchronization Therapy: Results from the RIDE-CRT Study
Lacour, P., Dang, P. L., Morris, D. A., Parwani, A. S., Doehner, W., Schuessler, F., Hohendanner, F., Heinzel, F. R., Stroux, A., Tschöepe, C., et al. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12675 · Cited by 15
Clinical and imaging outcomes after intermediate‐ or high‐risk pulmonary embolus
Lachant, D. J., Bach, C., Wilson, B. L., Chengazi, V., Goldman, B., Lachant, N. A., Pietropaoli, A. P., Cameron, S. J., & White, R. J. (2020) · Pulmonary Circulation · doi:10.1177/2045894020952019 · Cited by 16
“Hospitalization duration (days) 4 (3, 8) 6 (3, 7) 4 (3,8) 13 (5, 19)”
Fibroblast Growth Factor 23 and Exercise Capacity in Heart Failure with Preserved Ejection Fraction
Ghuman, J. K., Cai, X., Patel, R. B., Khan, S. S., Hecktman, J., Redfield, M. M., Lewis, G. D., Shah, S. J., Wolf, M. S., Isakova, T., et al. (2020) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2020.09.477 · Cited by 15
An evaluation of ferric derisomaltose as a treatment for anemia
Kassianides, X., Bodington, R., & Bhandari, S. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2021.1858406 · Cited by 13
Chobufo, M. D., Rahman, E. U., Gayam, V. B. R., Foryoung, J. B., Agbor, V. N., Farah, F., Dufresne, A., Nfor, T., & El-Hamdani, M. O. (2021) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.1080/20009666.2020.1854927 · Cited by 20
“Of note, correction of iron deficiency is associated with improved outcomes [3,4] that has prompted leading cardiology organizations to issue a class IIb recommendation screening and correction of ID in patients with HF [5,6].”
BackgroundSafety and efficacy of a single total dose infusion (1020 mg) of ferumoxytol
Khan, H., May, P., Kuo, E., Pai, P., Boles, K., McGee, A., Dang, T., & Schmit, J. M. (2021) · Therapeutic Advances in Hematology · doi:10.1177/20406207211006022 · Cited by 14
Anker, S. D., Ponikowski, P. P., Khan, M. S., Friede, T., Jankowska, E. A., Fabien, V., Goehring, U.-M., Metra, M., Piña, I. L., Coats, A. J. S., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2491 · Cited by 14
Self-citation
Metadata
- Authors
- Anker, S. D., Comin Colet, J., Filippatos, G., Willenheimer, R., Dickstein, K., Drexler, H., Lüscher, T. F., Bart, B., Banasiak, W., Niegowska, J., Kirwan, B.-A., Mori, C., von Eisenhart Rothe, B., Pocock, S. J., Poole-Wilson, P. A., & Ponikowski, P.
- Affiliations
- Stavanger University Hospital (NO)
- Lund University (SE)
- University of Bergen (NO)
- Medizinische Hochschule Hannover (DE)
- University Hospital Zurich (CH)
- Pirogov Russian National Research Medical University (RU)
- State Oil Company of Azerbaijan Republic (Azerbaijan) (AZ)
- Vifor Pharma (Switzerland) (CH)
- London School of Hygiene & Tropical Medicine (GB)
- Imperial College London (GB)
- Wroclaw Medical University (PL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-12-17
- Volume
- 361
- Issue
- 25
- Pages
- 2436-2448
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2148669301
- Cited by
- 2,083
- References
- 26
- Citations by year
- 2026: 101 · 2025: 131 · 2024: 145 · 2023: 156 · 2022: 162 · 2021: 190 · 2020: 128 · 2019: 129 · 2018: 113 · 2017: 133 · 2016: 101 · 2015: 115 · 2014: 102 · 2013: 93 · 2012: 106
- FWCI
- 62.22
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- ABACUS. Repositorio de Producción Científica (Universidad Europea) (submittedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion, other-oa)
- University of Bedfordshire Repository (University of Bedfordshire) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Amgen
- Teva Pharmaceutical Industries
- Vifor Pharma
- Servier
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- ferric carboxymaltose, intravenous iron, chronic heart failure, iron deficiency, anemia, reduced left ventricular ejection fraction, NYHA functional class, symptom improvement, functional capacity, 6-minute walk test, health-related quality of life, ferritin, transferrin saturation, adverse events, mortality, serious adverse events, iron deficiency anemia
- MeSH terms
- Iron Deficiencies, Aged, Chronic Disease, Female, Ferric Compounds, Ferritins, Follow-Up Studies, Heart Failure, Hematinics, Humans, Male, Maltose, Quality of Life, Stroke Volume, Ventricular Dysfunction, Left, Anemia, Iron-Deficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.